Related Experiment Video
Updated: Dec 11, 2025

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine
Published on: November 4, 2018
[Phenylketonuria, from diet to gene therapy]
Arnaud Wiedemann1, Abderrahim Oussalah2, Élise Jeannesson2
1Centre de référence des maladies métaboliques, Service de pédiatrie, CHRU de Nancy, 54000 Nancy, France - Inserm UMR_S 1256 (NGERE, Nutrition Génétique et Exposition aux Risques Environnementaux), Faculté de médecine de Nancy, Université de Lorraine, 54000 Nancy, France.
Insights
Phenylketonuria (PKU) management has improved with early screening and diet. New treatments like gene therapy offer hope for better phenylketonuria (PKU) patient outcomes, addressing challenges with current therapies.
Area of Science:
- Biochemistry
- Genetics
- Pharmacology
Background:
- Phenylketonuria (PKU) is a genetic disorder.
- Neonatal screening and low-phenylalanine diets have improved PKU prognosis.
- Lifelong dietary management presents significant compliance challenges.
Purpose of the Study:
- To review the pathophysiology of phenylketonuria (PKU).
- To discuss current and emerging therapeutic strategies for PKU.
- To evaluate the effectiveness and limitations of existing PKU treatments.
Main Methods:
- Literature review of PKU pathophysiology.
- Analysis of current PKU treatments (dietary, sapropterin, enzyme therapy).
- Exploration of novel therapeutic modalities, including gene therapy.
Main Results:
- Sapropterin (BH4) benefits a subset of PKU patients.
- Subcutaneous enzyme therapy shows promise but has side effects.
- Gene therapy represents a significant area of ongoing PKU research.
Conclusions:
- Despite advances, PKU management requires improved patient compliance and efficacy.
- Emerging therapies, particularly gene therapy, hold potential for transformative PKU treatment.
- Further research is crucial to overcome PKU treatment limitations.
Abstract:
The prognosis for phenylketonuria (PKU) has been improved by neonatal screening and dietary management via a low-phenylalanine diet. This treatment must be followed throughout life, which induces severe compliance problems. Drug treatment with sapropterin (or BH4) has come to help a reduced percentage of patients who respond to this drug. A subcutaneous enzyme therapy is available in the USA and has obtained European marketing authorization, but generates significant side effects, which limits its effectiveness. New therapeutic options for PKU are currently being developed, in particular gene therapy. The purpose of this article is to take stock of the pathophysiology and the various new therapeutic modalities currently in development.
Related Concept Videos
Inborn Errors of Metabolism
Gene Therapy
Overview of Protein Metabolism
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Chronic Kidney Disease III: Interprofessional Care
What is Genetic Engineering?
In-vitro Mutagenesis

